Saxena White P.A. is pleased to announce that on November 19, 2025, the United States District Court for the Southern District of New York appointed Victor Otcheretko as Lead Plaintiff and Saxena White P.A. as Lead Counsel in the securities class action against Neumora Therapeutics Inc., several executive officers, and underwriters of Neumora’s initial public offering (the “IPO”).

The action alleges that the offering documents for Neumora’s IPO contained untrue statements of material fact and/or omitted to state material adverse facts about and major risks concerning the reliability of Phase 2 trial results for Navacaprant, Neumora’s flagship therapeutic candidate aimed at treating major depressive disorder (MDD).